Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers will conduct a randomized, double-blind, multi-center clinical trial to assess the effectiveness of YH0618 granule in preventing chemotherapy-induced hair loss among breast cancer patients, aiming to understand its mechanism related to kidney deficiency in Chinese Medicine. Results are not yet reported.

This study found that scalp cooling effectively prevented chemotherapy-induced alopecia in patients, with a higher success rate observed in those who did not receive anthracyclines, although some experienced scalp pain and other mild adverse effects.

In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.

This study will evaluate the clinical efficacy, patient-reported outcomes, and economic impact of the PAXMAN® PSCS 2 automated scalp cooling system versus standard cold-cap therapy to prevent chemotherapy-induced hair loss in women with localized breast cancer during anthracycline and taxane treatment.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

This study found that DVd therapy is at least as effective as VAD/VAd for treating multiple myeloma and causes fewer side effects and reduced hospital visits.

In this study, scalp hypothermia with the Theracool™ cooling machine was largely ineffective for preventing alopecia in breast cancer patients undergoing a chemotherapeutic regimen including cyclophosphamide and anthracyclines.

In this randomized controlled trial involving breast cancer patients undergoing chemotherapy, this study investigated the efficacy of low-level light therapy for preventing hair loss, measuring outcomes like hair count and patient quality of life, but the abstract does not report specific results.

This opinion piece discusses strategies for managing cancer-related alopecia, emphasizing personalized approaches including scalp cooling and topical minoxidil, but it reports no new clinical results.

This review summarizes the use and neonatal outcomes of chemotherapy during pregnancy, noting its potential for safe use in the second and third trimesters, and reports no new clinical results.

This article reviews adverse skin reactions caused by chemotherapy and cytokine treatments, describing specific and nonspecific reactions, but reports no new clinical findings.

In this descriptive study, researchers assessed the most common short-term side effects of anthracycline and taxane-based chemotherapy in 122 Moroccan women with localized breast cancer, documenting frequent systemic, gastrointestinal, dermatological, neurological, musculoskeletal, and ocular toxicities.

This study aims to evaluate the effectiveness of YH0618 granules in preventing chemotherapy-induced hair loss in breast cancer patients through a randomized, double-blind, multi-center clinical trial, focusing on potential mechanisms related to kidney deficiency as understood in Chinese Medicine. Results are not yet reported.

This scoping review found that chemotherapy-induced alopecia in breast cancer patients, especially when using anthracycline- and taxane-based regimens, occurs at higher rates and with more persistence than historically reported.

This study found that scalp cooling markedly reduces cellular uptake of anthracycline drugs in human keratinocytes, partially explaining its protective effect against chemotherapy-induced cytotoxicity.

This study found that both scalp cooling systems and chemical cooling caps effectively reduced chemotherapy-induced alopecia in early breast cancer patients, with scalp cooling showing better early efficacy but chemical cooling providing greater psychological and quality of life benefits.

In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.

This review provides a comprehensive overview of multidisciplinary dermo-aesthetic interventions for breast cancer patients, aiming to establish safe protocols involving various specialists to improve quality of life, although consultation with an oncologist before treatment is advised.

This study evaluated emerging techniques for managing chemotherapy-induced alopecia and found that scalp cooling significantly reduced hair loss, while photobiomodulation was well-tolerated without major adverse effects; however, further research is needed to refine treatment protocols and ensure long-term safety.

In this study, researchers used a patient-reported outcome questionnaire to assess long-term adverse effects in breast cancer patients undergoing chemotherapy, finding persistent symptoms like neuropathy, dysgeusia, insomnia, and nail loss. Peripheral neuropathy was notably prolonged in those receiving anthracycline- and taxane-based regimens compared to docetaxel/cyclophosphamide.

This article discusses the importance of optimizing treatment protocols for chemotherapy-induced alopecia and reports no new clinical results; the authors emphasize improving patient outcomes and quality of life.

The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.

This review describes the unique pharmacological profile and clinical applications of pegylated liposomal doxorubicin, emphasizing its role in Kaposi's sarcoma and recurrent ovarian cancer, but reports no new clinical results.

This review discusses the enhanced permeability and retention (EPR) effect as a mechanism for targeted drug delivery in cancer therapy and reports no new clinical results.

In this study, manual cold capping was found to be effective in minimizing chemotherapy-induced alopecia, with 92.1% of patients retaining 50% or more of their hair, although effectiveness varied with different chemotherapy regimens.

This study found that patient-reported outcomes revealed the persistence of neuropathy, insomnia, and nail changes in breast cancer patients beyond chemotherapy, emphasizing the importance of monitoring long-term adverse events.

In this study, researchers explored the use of new biobased compounds and gels as potential treatments for skin cancer, finding that these biological materials may be significant in limiting and eliminating skin tumors alone or when combined with other methods.

This article reviews the identification and assessment of cutaneous drug reactions, emphasizing the importance of early recognition and the need for accurate diagnosis to prevent serious complications; it reports no new clinical results.

This chapter reviews the structure, pharmacokinetics, and clinical applications of PEGylated liposomes and reports no new research findings.

This paper provides an overview of scalp cooling as an effective and safe intervention for preventing chemotherapy-induced alopecia, addressing its impact on cancer patients and survivors.